This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Shire Pharmaceuticals Group PLC

Drug Names(s): Dextroamphetamine/Amphetamine, SHP465, SPD465, triple-bead mixed amphetamine salts (MAS)

Description: SPD465 has the same active ingredient asADDERALL XR (mixed salts of a single-entity amphetamine product), but isdesigned to provide ADHD symptom control for up to 16 hours.

Deal Structure: Shire and Supernus
In December 2005, Supernus started its operations and it purchased all the assets of Shire Laboratories, Inc (a Shire subsidiary).

SHP465 was originally developed by Shire Laboratories, the former division of Shire that subsequently became Supernus Pharmaceuticals. Based on the agreement between Supernus and Shire, Shire will pay to Supernus a single digit percentage royalty on net sales of the product.

Abbvie and Shire
In July 2014, AbbVie and Shire announced that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.

Partners: Supernus Pharmaceuticals, Inc.

SHP465 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug